Compare OPXS & RANI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OPXS | RANI |
|---|---|---|
| Founded | 1987 | 2012 |
| Country | United States | United States |
| Employees | 72 | N/A |
| Industry | Electronic Components | Medicinal Chemicals and Botanical Products |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 90.5M | 106.9M |
| IPO Year | 2009 | 2021 |
| Metric | OPXS | RANI |
|---|---|---|
| Price | $13.97 | $0.77 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | ★ $16.10 | $7.50 |
| AVG Volume (30 Days) | 45.4K | ★ 663.2K |
| Earning Date | 05-11-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 34.55 | ★ 57.14 |
| EPS | ★ 0.23 | N/A |
| Revenue | ★ $24,530,000.00 | $1,633,000.00 |
| Revenue This Year | $39.17 | $274.77 |
| Revenue Next Year | $0.53 | $79.44 |
| P/E Ratio | $61.00 | ★ N/A |
| Revenue Growth | 17.63 | ★ 58.85 |
| 52 Week Low | $9.74 | $0.39 |
| 52 Week High | $17.76 | $3.87 |
| Indicator | OPXS | RANI |
|---|---|---|
| Relative Strength Index (RSI) | 60.63 | 41.77 |
| Support Level | $12.46 | $0.71 |
| Resistance Level | $13.68 | $0.83 |
| Average True Range (ATR) | 0.78 | 0.04 |
| MACD | 0.08 | 0.00 |
| Stochastic Oscillator | 78.05 | 42.31 |
Optex Systems Holdings Inc manufactures optical sighting systems and assemblies for the U.S. Department of Defense, foreign military applications, and commercial markets. Its products are installed on a variety of United States military land vehicles, such as the Abrams and Bradley fighting vehicles, light armored and security vehicles, and have been selected for installation on the Stryker family of vehicles. The company's operating segment includes Optex Systems Richardson, Applied Optics Center Dallas, and others. It generates maximum revenue from the Optex Systems Richardson segment. Some of its products include M17 Day/Thermal Periscope; DDAN / M36 Sights; Laser Protected Periscopes; Muzzle Reference Sensor, and others.
Rani Therapeutics Holdings Inc is a clinical-stage biotherapeutics company advancing technologies to enable the development of orally administered biologics to provide patients, physicians, and healthcare systems with a convenient alternative to painful injections. The company has developed the RaniPill capsule, which is designed to deliver a wide variety of drug substances, including antibodies, proteins, peptides, and oligonucleotides. RaniPill is a proprietary and patented platform technology, intended to replace subcutaneous or IV injection of biologics with oral dosing. The company is also engaged in developing RaniPill HC, which is intended to enable the delivery of drug payloads in liquid form with high bioavailability.